FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-014620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Thuy Trinh Nguyen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. Hauptthemen laut MEDLINE: Dendritic Cells, CD40 Antigens, Programmed Cell Death 1 Receptor, Membrane Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge for immunotherapy due to its immunologically cold tumor nature, characterized by poor T cell infiltration and a highly suppressive tumor microenvironment. Here, we propose a novel strategy, combining fibroblast activation protein (FAP)-CD40 to activate dendritic cells (DCs) in the tumor microenvironment and programmed cell death protein-1 (PD1)-interleukin 2v (IL2v) to promote the expansion and differentiation of tumor-infiltrating T cells. We hypothesize that this combination will synergistically enhance both T cell priming and expansion directly within pancreatic 4662 KPC tumors, which recapitulate the immunologically cold features of human PDAC.
Methods
Immune cell distribution and abundance following FAP-CD40/PD1-IL2v monotherapy or combination therapy were analyzed using multiplexed confocal imaging (3D immune phenotyping). FTY720 studies assessed the contribution of lymph node priming in treatment efficacy, while CD4+/CD8+ T cell depletion experiments identified the roles of these subsets in combination therapy. T cell functionality was further assessed through ex vivo restimulation assays and single-cell RNA sequencing.
Results
Combination therapy induced dense intratumoral clusters of CD4 + and CD8 + T cells, colocalized with type 1 conventional DCs, termed as T cell-DC clusters (TDCs). These TDCs were strongly associated with tumor regression, which required both CD4 + and CD8 + T cells. Furthermore, T cells from combination-treated tumors showed enhanced functionality, with increased tumor necrosis factor-alpha and interferon-gamma production compared with monotherapy groups. Single-cell RNA sequencing revealed polarization of CD4 + T cells toward a T helper cell 1 phenotype in combination-treated tumors.
Conclusion
The combination of FAP-CD40 and PD1-IL2v offers a promising strategy for treating poorly infiltrated, cold tumors. By driving T cell infiltration, promoting de novo TDC formation and orchestrating local antitumor immunity, this strategy provides a foundation for future therapies targeting immunotherapy-resistant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
- Institute of Experimental Immunology, Universität Zürich, Zürich, Switzerland.
- Department of Immunology, Heidelberg University Medical Faculty Mannheim, Mannheim, Germany.
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland leo.kunz@roche.com.
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Nguyen, T. T., Gómez, H., Lutge, M., Yángüez, E., Hüsser, T., Nassiri, S., Trumpfheller, C., Colombetti, S., Codarri Deak, L., Umaña, P., Tugues, S., Grazina de Matos, I., & Kunz, L. (2026). FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014620
Vancouver
Nguyen TT, Gómez H, Lutge M, Yángüez E, Hüsser T, Nassiri S, et al. FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014620
BibTeX
@article{Nguyen2026,
author = {Nguyen, Thuy Trinh and Gómez, Harold and Lutge, Mechthild and Yángüez, Emilio and Hüsser, Tamara and Nassiri, Sina and Trumpfheller, Christine and Colombetti, Sara and Codarri Deak, Laura and Umaña, Pablo and Tugues, Sònia and Grazina de Matos, Ines and Kunz, Leo},
title = {FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-014620}
}
EUVIMED